Author

Analía Meilerman Abuelafia

Centre National de la Recherche Scientifique

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Approach:experimental assay· 1 Organism:human· 1 Assay:proteomics· 1

Frequent Co-Authors

Daniel GrassoiD· 1 shared Eduardo ChuluyániD· 1 shared Gwen Alyce LomberkiD· 1 shared Juan IovannaiD· 1 shared Matías EstarásiD· 1 shared Nelson DusettiiD· 1 shared Nicolas Alejandro FraunhofferiD· 1 shared Patricia Santofimia‐CastañoiD· 1 shared

Activity by Year

2025-2025 · peak 1/yr

Co-Author Collaboration Network

9 top collaborators · 36 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Daniel GrassoORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Cancer BiologyTranslational OncologyPeer-reviewedMay 17, 2025

KRAS Inhibition Reverses Chemotherapy Resistance Promoted by Therapy-Induced Senescence-like in Pancreatic Ductal Adenocarcinoma

Analía Meilerman Abuelafia, Patricia Santofimia‐Castaño, Matías Estarás…·Juan Iovanna

This study shows that KRAS inhibition can reverse chemotherapy resistance in PDAC by targeting therapy-induced senescence-like cells, with ERK pathway involvement.

6 citations

humanbulk RNA-seq

𝕏 PostBluesky